107259-06-3

Basic information

• Product Name: TERT-BUTYL (1-FORMYLCYCLOPROPYL)CARBAMATE
• Synonyms: TERT-BUTYL (1-FORMYLCYCLOPROPYL)CARBAMATE;(1-Formyl-cyclopropyl)-carbamic acid tert-butyl ester;1-((pivaloyloxy)amino)cyclopropanecarbaldehyde;1-(tert-Butoxycarbonylamino)cyclopropanecarboxaldehyde;1-(tert-Butoxycarbonylamino)cyclopropanecarboxaldehyde (1-Formylcyclopropyl)carbamic acid tert-butyl ester;Carbamic acid, N-(1-formylcyclopropyl)-, 1,1-dimethylethyl ester;tert-Butyl(l -formylcyclopropyl)carbamate
• CAS NO: 107259-06-3
• Molecular Formula: C₉H₁₅NO₃
• Molecular Weight: 185.22
• Mol File: 107259-06-3.mol

Chemical Properties

• Melting Point: 76.5-78.50℃
• Boiling Point: 280.708 °C at 760 mmHg
• Flash Point: 123.568 °C
• Appearance: /
• Density: 1.102 g/cm³
• PKA: 10.88±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL (1-FORMYLCYCLOPROPYL)CARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL (1-FORMYLCYCLOPROPYL)CARBAMATE(107259-06-3)
• EPA Substance Registry System: TERT-BUTYL (1-FORMYLCYCLOPROPYL)CARBAMATE(107259-06-3)

Safety Data

• Hazardous Substances Data: 107259-06-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Tert-Butyl (1-formylcyclopropyl)carbamate is used as a reagent for the preparation of various pharmaceuticals and agrochemicals, due to its stability and compatibility with a wide range of reaction conditions. It aids in the synthesis of complex organic molecules.
Used as a Protecting Group in Organic Chemistry:
Tert-Butyl (1-formylcyclopropyl)carbamate is used as a protecting group for amines, allowing chemists to temporarily block the reactivity of amine groups during organic synthesis, facilitating the selective modification of other functional groups in the molecule.
Used in Agrochemicals:
Tert-Butyl (1-formylcyclopropyl)carbamate is used as a herbicidal and insecticidal agent, leveraging its chemical properties to control the growth of unwanted plants and insects in agricultural settings.

Upstream product

• 161521-10-4 1-<(t-butoxycarbonyl)amino>cyclopropane-1-carbonyl-N,O-dimethylhydroxylamide 
• 88950-64-5 1-<(tert-butyloxy)carbonylamino>cyclopropane-1-carboxylic acid 
• 107259-05-2 1-tert-butoxycarbonylamino-cyclopropanecarboxylic Acid Ethyl Ester 
• 107017-73-2 tert-butyl (1-(hydroxymethyl)cyclopropyl)carbamate 

Downstream Products

• 1027338-34-6 tert-butyl N-[1-(aminomethyl)cyclopropyl]carbamate 
• 1268810-09-8 tert-butyl N-(1-ethynylcyclopropyl)carbamate 
• 1414358-09-0 tert-butyl N-[1-[3-[(2R)-2-[[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]pyrrolidin-1-yl]-2-cyano-3-oxo-prop-1-enyl]cyclopropyl]carbamate 

Relevant articles and documents

The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K

Irreversible covalent inhibitors can have a beneficial pharmacokinetic/pharmacodynamics profile but are still often avoided due to the risk of indiscriminate covalent reactivity and the resulting adverse effects. To overcome this potential liability, we introduced an alkyne moiety as a latent electrophile into small molecule inhibitors of cathepsin K (CatK). Alkyne-based inhibitors do not show indiscriminate thiol reactivity but potently inhibit CatK protease activity by formation of an irreversible covalent bond with the catalytic cysteine residue, confirmed by crystal structure analysis. The rate of covalent bond formation (kinact) does not correlate with electrophilicity of the alkyne moiety, indicative of a proximity-driven reactivity. Inhibition of CatK-mediated bone resorption is validated in human osteoclasts. Together, this work illustrates the potential of alkynes as latent electrophiles in small molecule inhibitors, enabling the development of irreversible covalent inhibitors with an improved safety profile.

Discovery of Novel Inhibitors of LpxC Displaying Potent in Vitro Activity against Gram-Negative Bacteria

UDP-3-O-((R)-3-hydroxymyristoyl)-N-glucosamine deacetylase (LpxC) is as an attractive target for the discovery and development of novel antibacterial drugs to address the critical medical need created by multidrug resistant Gram-negative bacteria. By using a scaffold hopping approach on a known family of methylsulfone hydroxamate LpxC inhibitors, several hit series eliciting potent antibacterial activities against Enterobacteriaceae and Pseudomonas aeruginosa were identified. Subsequent hit-to-lead optimization, using cocrystal structures of inhibitors bound to Pseudomonas aeruginosa LpxC as guides, resulted in the discovery of multiple chemical series based on (i) isoindolin-1-ones, (ii) 4,5-dihydro-6H-thieno[2,3-c]pyrrol-6-ones, and (iii) 1,2-dihydro-3H-pyrrolo[1,2-c]imidazole-3-ones. Synthetic methods, antibacterial activities and relative binding affinities, as well as physicochemical properties that allowed compound prioritization are presented. Finally, in vivo properties of lead molecules which belong to the most promising pyrrolo-imidazolone series, such as 18d, are discussed.

CATHEPSIN INHIBITORS

This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Cathepsin K (CatK), and to a method of inhibiting cathepsin activity, comprising administering a compound or formulation comprising a compound according to the invention.

CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS

The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPRl) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the tr

ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES

The invention relates to antibacterial compounds of formula I wherein X represents sulphur or CH=CH; R1 represents H, PO3H2, SO3H, phosphonooxymethyl or the group -CO-R2 wherein R2 is as defined in the claims M is one of the groups MA and MB represented below wherein A represents a bond or C≡C and R1A, R2A, R3A and R1B are as defined in the claims; and to salts thereof.

ANTIBACTERIAL HETEROCYCLIC DERIVATIVES

The invention relates to antibacterial compounds of formula (I), wherein R1, M, R2, R3, and V are as described in the description, to their preparation, to salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as antibacterial agents.

SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS

The invention relates to antibacterial compounds of formula (I) wherein M is one of the groups MA, MB and MC represented below wherein R1, MA, MB and MC are as defined in the specification; and to salts thereof.

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

Technological synthesis method of 1-amino cyclopropyl acetylene

The invention discloses a technological synthesis method of 1-amino cyclopropyl acetylene. The method includes: taking compound 1 as the starting material, and carrying out oxidation, Corey-Fuchs reaction, and amino protection group removal so as to obtain the 1-amino cyclopropyl acetylene. The reagents and raw materials used by the method provided by the invention are cheap and easily available, and low in cost. With the advantages of high reaction safety, simple operation and high yield, the method is suitable for industrial scale-up production. (with the synthesis process shown as the specification).

TREATMENT OF DRY EYE

The present disclosure provides a method of treating dry eye by inhibition of Bruton's tyrosine kinase (hereinafter "BTK") inhibitors, pharmaceutical formulations comprising the same, and processes for preparing such compounds.